Gain Therapeutics, Inc. ( (GANX) ) has released its Q2 earnings. Here is a breakdown of the information Gain Therapeutics, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation allosteric small molecule therapies, particularly for neurodegenerative diseases such as Parkinson’s disease. The company is known for its unique approach using the Magellan™ platform to discover novel treatments.
In its second-quarter 2025 earnings report, Gain Therapeutics announced the successful completion of full enrollment for its Phase 1b study of GT-02287, a promising drug candidate for Parkinson’s disease. The company also highlighted a public offering that raised $7.1 million, extending its financial runway.
Key financial metrics revealed a decrease in research and development expenses to $2.8 million and general and administrative expenses to $2.3 million, contributing to a reduced net loss of $0.19 per share compared to $0.42 in the previous year. The company also reported cash and cash equivalents of $6.7 million as of June 30, 2025.
Looking ahead, Gain Therapeutics is preparing for the analysis of functional changes and biomarker activity in its Phase 1b study, expected in the fourth quarter of 2025. The company is also planning to submit an IND to the FDA by the end of 2025 to expand its Phase 2 clinical development in the United States.
Gain Therapeutics remains optimistic about its future, with ongoing efforts to advance its clinical programs and potentially shift the treatment paradigm for Parkinson’s disease and other neurodegenerative disorders.